Global Emerging Therapeutics for Hematological Malignancies Market 2022 - Industry Briefing

November 2022 | 50 pages | ID: GFF5B96AD16BEN
Gen Consulting Company

Abstracts

The global emerging therapeutics for hematological malignancies market is anticipated to increase by USD 12.0 billion till 2028 at an average annual growth of 13.4 percent as per the latest report by Gen Consulting Company.

This industry report offers market estimates of the global market, followed by a detailed analysis of the type, indication, and region. The global market data on emerging therapeutics for hematological malignancies can be segmented by type: CAR T-cell therapies, monoclonal antibodies. The monoclonal antibodies segment was the largest contributor to the global emerging therapeutics for hematological malignancies market in 2021. Emerging therapeutics for hematological malignancies market is further segmented by indication: leukemia, lymphoma, multiple myeloma. Based on region, the emerging therapeutics for hematological malignancies market is segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW).

The CAR T-cell therapies market is further segmented into tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), others. Furthermore, the monoclonal antibodies market has been categorized into blinatumomab (Blincyto), brentuximab vedotin (Adcetris), daratumumab (Darzalex), inotuzumab ozogamicin (Besponsa), obinutuzumab (Gazyva), sintilimab (Tyvyt), others.

The global emerging therapeutics for hematological malignancies market is highly competitive. Top players covered in Global Emerging Therapeutics for Hematological Malignancies Market Study are AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics Inc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?

• Get a detailed picture of the Global Emerging Therapeutics for Hematological Malignancies Market
• Identify segments/areas to invest in over the forecast period in the Global Emerging Therapeutics for Hematological Malignancies Market
• Understand the competitive environment, the market’s leading players
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. SUMMARY

PART 2. INTRODUCTION

Study period
Geographical scope
Market segmentation

PART 3. EMERGING THERAPEUTICS FOR HEMATOLOGICAL MALIGNANCIES MARKET OVERVIEW

PART 4. MARKET BREAKDOWN BY TYPE

CAR T-cell therapies
Monoclonal antibodies

PART 5. MARKET BREAKDOWN BY INDICATION

Leukemia
Lymphoma
Multiple myeloma

PART 6. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
North America
Rest of the World (RoW)

PART 7. KEY COMPANIES

AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Company (BMS)
F. Hoffmann-La Roche AG
Gilead Sciences, Inc.
GlaxoSmithKline plc
Immune-Onc Therapeutics, Inc.
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited

PART 8. METHODOLOGY